These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29060995)

  • 1. [Bias risk assessment: (3) Revised Cochrane bias risk assessment tool for individual randomized, cross-over trials (RoB2.0)].
    Wu SS; Sun F; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Oct; 38(10):1436-1440. PubMed ID: 29060995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk on bias assessment: (2) Revised Cochrane risk of bias tool for individually randomized, parallel group trials (RoB2.0)].
    Yang ZR; Sun F; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Sep; 38(9):1285-1291. PubMed ID: 28910948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk related to bias assessment: (4) Revised Cochrane Risk of Bias Tool for cluster-randomized control trials (RoB2.0)].
    Lyu XZ; Sun F; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Feb; 39(2):240-244. PubMed ID: 29495213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability of the revised Cochrane risk-of-bias tool for randomised trials (RoB2) improved with the use of implementation instruction.
    Minozzi S; Dwan K; Borrelli F; Filippini G
    J Clin Epidemiol; 2022 Jan; 141():99-105. PubMed ID: 34537386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence of systematic reviews to Cochrane RoB2 guidance was frequently poor: a meta epidemiological study.
    Minozzi S; Gonzalez-Lorenzo M; Cinquini M; Berardinelli D; Cagnazzo C; Ciardullo S; De Nardi P; Gammone M; Iovino P; Lando A; Rissone M; Simeone G; Stracuzzi M; Venezia G; Moja L; Costantino G;
    J Clin Epidemiol; 2022 Dec; 152():47-55. PubMed ID: 36156301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Series of risk of bias assessment (5): Risk Of Bias In Non-randomized Studies-of Interventions (ROBINS-I)].
    Sun F; Gao L; Yang ZR; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Mar; 39(3):374-381. PubMed ID: 29609257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews.
    Jørgensen L; Paludan-Müller AS; Laursen DR; Savović J; Boutron I; Sterne JA; Higgins JP; Hróbjartsson A
    Syst Rev; 2016 May; 5():80. PubMed ID: 27160280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of the Risk of Bias 2 Tool].
    Lee LL
    Hu Li Za Zhi; 2021 Apr; 68(2):85-91. PubMed ID: 33792022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research Quality of Clinical Trials Reported for Foods with Function Claims in Japan, 2023-2024: Evaluation Based on a Revised Tool to Assess Risk of Bias in Randomized Trials.
    Kamioka H; Kitayuguchi J; Origasa H; Tsutani K
    Nutrients; 2024 Aug; 16(16):. PubMed ID: 39203880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies.
    Barker TH; Habibi N; Aromataris E; Stone JC; Leonardi-Bee J; Sears K; Hasanoff S; Klugar M; Tufanaru C; Moola S; Munn Z
    JBI Evid Synth; 2024 Mar; 22(3):378-388. PubMed ID: 38287725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of bias in randomized trials of pharmacological interventions in children and adults.
    Sinha YK; Craig JC; Sureshkumar P; Hayen A; Brien JA
    J Pediatr; 2014 Aug; 165(2):367-371.e1. PubMed ID: 24814415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automating risk of bias assessment for clinical trials.
    Marshall IJ; Kuiper J; Wallace BC
    IEEE J Biomed Health Inform; 2015 Jul; 19(4):1406-12. PubMed ID: 25966488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-of-bias assessment using Cochrane's revised tool for randomized trials (RoB 2) was useful but challenging and resource-intensive: observations from a systematic review.
    Crocker TF; Lam N; Jordão M; Brundle C; Prescott M; Forster A; Ensor J; Gladman J; Clegg A
    J Clin Epidemiol; 2023 Sep; 161():39-45. PubMed ID: 37364620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of risk of bias in randomized clinical trials in surgery.
    Gurusamy KS; Gluud C; Nikolova D; Davidson BR
    Br J Surg; 2009 Apr; 96(4):342-9. PubMed ID: 19283747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research.
    Armijo-Olivo S; Stiles CR; Hagen NA; Biondo PD; Cummings GG
    J Eval Clin Pract; 2012 Feb; 18(1):12-8. PubMed ID: 20698919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews.
    Vale CL; Tierney JF; Burdett S
    BMJ; 2013 Apr; 346():f1798. PubMed ID: 23610376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk of bias assessment: (8) Risk of Bias in Systematic Review (ROBIS)].
    Hu J; Sun F; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Aug; 39(8):1125-1129. PubMed ID: 30180441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessments of the quality of randomized controlled trials published in International Journal of Urology from 1994 to 2011.
    Cho HJ; Chung JH; Jo JK; Kang DH; Cho JM; Yoo TK; Lee SW
    Int J Urol; 2013 Dec; 20(12):1212-9. PubMed ID: 23573913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROBINS-1: A tool for asssessing risk of bias in non-randomised studies of interventions.
    Hinneburg I
    Med Monatsschr Pharm; 2017 Apr; 40(4):175-7. PubMed ID: 29952172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events.
    Faillie JL; Ferrer P; Gouverneur A; Driot D; Berkemeyer S; Vidal X; Martínez-Zapata MJ; Huerta C; Castells X; Rottenkolber M; Schmiedl S; Sabaté M; Ballarín E; Ibáñez L
    J Clin Epidemiol; 2017 Jun; 86():168-175. PubMed ID: 28487158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.